CMS-D002

CMS-D002 is an oral, non-peptide small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist developed by China Medical System Holdings Limited (CMS) and its subsidiary Shenzhen Kangzhe Pharmaceutical. It acts by competitively binding to the GnRH receptor on the pituitary gland, thereby blocking the pituitary-gonadal axis at the central nervous system level. This results in reduced release of endogenous follicle-stimulating hormone (FSH) and luteinizing hormone (LH), leading to decreased secretion of downstream sex hormones such as estrogen, progesterone, and testosterone. The drug is being developed for sex hormone-related diseases including endometriosis, uterine fibroids, and prostate cancer. Compared with GnRH agonists used for similar indications, antagonists like CMS-D002 offer dose-dependent inhibition of sex hormones with rapid restoration of gonadal function after withdrawal[6][8]. As of 2024, it is in Phase 1 clinical trials evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult premenopausal female subjects[1][2][6].